Back to Search Start Over

Inter-fraction motion robustness and organ sparing potential of proton therapy for cervical cancer.

Authors :
Gort, Elske M.
Beukema, Jannet C.
Matysiak, Witold
Sijtsema, Nanna M.
Aluwini, Shafak
Langendijk, Johannes A.
Both, Stefan
Brouwer, Charlotte L.
Source :
Radiotherapy & Oncology. Jan2021, Vol. 154, p194-200. 7p.
Publication Year :
2021

Abstract

[Display omitted] • Proton therapy can be as robust as photon therapy to inter-fraction motion. • Proton therapy significantly reduces organ at risk doses compared to photon therapy. • Two ITV-based treatment planning techniques for PBS-PT presented. Large-field photon radiotherapy is current standard in the treatment of cervical cancer patients. However, with the increasing availability of Pencil Beam Scanning Proton Therapy (PBS-PT) and robust treatment planning techniques, protons may have significant advantages for cervical cancer patients in the reduction of toxicity. In this study, PBS-PT and photon Volumetric Modulated Arc Therapy (VMAT) were compared, examining target coverage and organ at risk (OAR) dose, taking inter- and intra-fraction motion into account. Twelve cervical cancer patients were included in this in-silico planning study. In all cases, a planning CT scan, five weekly repeat CT scans (reCTs) and an additional reCT 10 min after the first reCT were available. Two-arc VMAT and robustly optimised two- and four-field (2F and 4F) PBS-PT plans were robustly evaluated on planCTs and reCTs using set-up and range uncertainty. Nominal OAR doses and voxel-wise minimum target coverage robustness were compared. Average voxel-wise minimum accumulated doses for pelvic target structures over all patients were adequate for both photon and proton treatment techniques (D98 > 95%, [91.7–99.3%]). Average accumulated dose of the para-aortic region was lower than the required 95%, D98 > 94.4% [91.1–98.2%]. With PBS-PT 4F, dose to all OARs was significantly lower than with VMAT. Major differences were observed for mean bowel bag V 15Gy : 60% [39–70%] for VMAT vs 30% [10–52%] and 32% [9–54%] for PBS-PT 2F and 4F and for mean bone marrow V 10Gy : 88% [82–97%] for VMAT vs 66% [60–73%] and 67% [60–75%] for PBS-PT 2F and 4F. Robustly optimised PBS-PT for cervical cancer patients shows equivalent target robustness against inter- and intra-fraction variability compared to VMAT, and offers significantly better OAR sparing. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
01678140
Volume :
154
Database :
Academic Search Index
Journal :
Radiotherapy & Oncology
Publication Type :
Academic Journal
Accession number :
149154086
Full Text :
https://doi.org/10.1016/j.radonc.2020.09.022